Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
Alessandro Vitale, Giuseppe Cabibbo, Massimo Iavarone, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 7, pp. e312-e322
Closed Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 30
Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal
Franco Trevisani, Alessandro Vitale, Masatoshi Kudo, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 4, pp. 661-669
Closed Access | Times Cited: 25
EASL position paper on clinical follow-up after HCV cure
Thomas Reiberger, Sabela Lens, Giuseppe Cabibbo, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 326-344
Closed Access | Times Cited: 24
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice
Giuseppe Cabibbo, Ciro Celsa, Lorenza Rimassa, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 957-966
Open Access | Times Cited: 21
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults
Abid Suddle, Helen L. Reeves, Richard Hubner, et al.
Gut (2024) Vol. 73, Iss. 8, pp. 1235-1268
Open Access | Times Cited: 18
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
Fabio Piscaglia, Gianluca Masi, Erika Martinelli, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104110-104110
Closed Access | Times Cited: 3
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
Journal of Hepatology (2023) Vol. 80, Iss. 3, pp. 431-442
Open Access | Times Cited: 32
Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation
Michael Li, Sherrie Bhoori, Neil Mehta, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 743-755
Closed Access | Times Cited: 16
Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges
Shunzhen Zheng, Siew Wee Chan, Fei Liu, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1582-1582
Open Access | Times Cited: 15
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma
Alessandro Vitale, Pierluigi Romano, Umberto Cillo, et al.
JAMA Surgery (2024) Vol. 159, Iss. 8, pp. 881-881
Closed Access | Times Cited: 13
Small-molecule-based targeted therapy in liver cancer
Ming Yue, Yanqiu Gong, Xuewen Fu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3260-3287
Closed Access | Times Cited: 11
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
Hepatology (2024)
Closed Access | Times Cited: 10
circCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation
Lei Yang, Wenliang Tan, Min Wang, et al.
Cancer Letters (2025) Vol. 612, pp. 217470-217470
Closed Access | Times Cited: 1
Hepatocellular carcinoma: Revising the surgical approach in light of the concept of multiparametric therapeutic hierarchy
Umberto Cillo, Enrico Gringeri, F. D’Amico, et al.
Digestive and Liver Disease (2025)
Closed Access | Times Cited: 1
Recurrence and survival after robotic vs laparoscopic liver resection in very-early to early-stage (BCLC 0-A) hepatocellular carcinoma
L. Bernardi, E Balzano, Raffaello Roesel, et al.
Surgical Endoscopy (2025)
Open Access | Times Cited: 1
Predictors of non-response to Atezolizumab plus Bevacizumab in patients with unresectable Hepatocellular Carcinoma: A Multicentre Real World Study (HCC-AB study)
Satender Pal Singh, Karan Kumar, Anand V. Kulkarni, et al.
Journal of Clinical and Experimental Hepatology (2025) Vol. 15, Iss. 4, pp. 102513-102513
Closed Access | Times Cited: 1
Tumour Biology Characteristics Score Based on AFP and PIVKA-II Predicts Recurrence and Survival After Curative Resection for Hepatocellular Carcinoma: A Multicentre Cohort Study
Ming‐Da Wang, B. Wang, Yong‐Kang Diao, et al.
Journal of Gastrointestinal Surgery (2025), pp. 102038-102038
Closed Access | Times Cited: 1
Dynamic prognostication and treatment planning for hepatocellular carcinoma: A machine learning-enhanced survival study using multi-centric data
Lujun Shen, Yiquan Jiang, Linbin Lu, et al.
The Innovation Medicine (2025), pp. 100125-100125
Closed Access | Times Cited: 1
METTL3-induced lncRNA GBAP1 promotes hepatocellular carcinoma progression by activating BMP/SMAD pathway
Runkun Liu, Guozhi Yin, Hang Tuo, et al.
Biology Direct (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 21
CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma
Feifan Yao, Suiqing Zhou, Ruizhi Zhang, et al.
Cancer Letters (2024) Vol. 593, pp. 216935-216935
Closed Access | Times Cited: 8
Liver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis
Pierluigi Romano, Marco Busti, Ilaria Billato, et al.
BJS Open (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 7
Advanced lung cancer inflammation index predicts overall survival of hepatocellular carcinoma after hepatectomy
Yuan-Zhang Wen, Gao‐Min Liu, Jia-Peng Liao, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects
Xuan-Yu Gu, Jinlong Huo, Yu Zhiyong, et al.
ONCOLOGIE (2024) Vol. 26, Iss. 1, pp. 9-25
Open Access | Times Cited: 6
Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate
Qifeng Chen, Song Chen, Minshan Chen, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 6
Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate‐stage Hepatocellular Carcinoma: A Multicenter Retrospective Study
Yitao Zheng, Yan‐Jun Xiang, Hongqi Shi, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1079-1093
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top